Immunotherapy combined with chemotherapy as second-line treatment may be a viable therapeutic option for NSCLC patients with double-ALK fusion when loss of double-fusion is the mechanism of ALK-TKIs resistance. This evidence concerns the gene ALK and non-small cell lung carcinoma.